Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2010; 31(03): 76-78
DOI: 10.4103/0971-5851.73588
COMMENTARY

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results

Arun Kumar Goel
Department of Surgical Oncology, Galaxy Cancer Institute, Pushpanjali Crosslay Hospital, W-3, Sector 1, Vaishali, Gaziabad, Uttar Pradesh, India
,
Malay Nandy
Department of Medical Oncology, Galaxy Cancer Institute, Pushpanjali Crosslay Hospital, W-3, Sector 1, Vaishali, Gaziabad, Uttar Pradesh, India
,
Gopal Sharma
Department of Medical Oncology, Galaxy Cancer Institute, Pushpanjali Crosslay Hospital, W-3, Sector 1, Vaishali, Gaziabad, Uttar Pradesh, India
› Author Affiliations Source of Support Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
19 November 2021

© 2010. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
  • 2 Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
  • 3 Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: A critical review. J Clin Oncol 2008;26:2568-81.
  • 4 Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: Review. Pathology 2009;41:40-7.
  • 5 Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
  • 6 Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
  • 7 Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
  • 8 Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
  • 9 Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
  • 10 Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
  • 11 Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
  • 12 Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
  • 13 Liedtke C, Mazouni C, Hess KR, Andrι F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
  • 14 Greenberg S, Rugo HS. Triple-negative breast cancer role of antiangiogenic agents. Cancer J 2010;16:33-8.
  • 15 Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant cisplatin in BRCA positive breast cancer patients. Breast Cancer Res Treat 2009;115:359-63.
  • 16 Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant cisplatin in triple negative breast cancer. J Clin Oncol 2010;28:1145-53.
  • 17 Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 2010;16:48-52.
  • 18 Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol 2009;27:No.15 Suppl:Abstr 551.